Product Description
Bimatoprost ophthalmic is used to treat glaucoma (a condition in which increased pressure in the eye can lead to gradual loss of vision) and ocular hypertension (a condition which causes increased pressure in the eye). Bimatoprost is in a class of medications called prostaglandin analogs. It lowers pressure in the eye by increasing the flow of natural eye fluids out of the eye. (Sourced from: https://medlineplus.gov/druginfo/meds/a602030.html)
Mechanisms of Action: EP1 Agonist,EP3 Agonist,PGF Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Ocular,Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Hypertension | Glaucoma | Hypertension | Glaucoma | Hypotrichosis
Known Adverse Events: Hyperemia | Eye Pain | Headache | Pain Unspecified | Photophobia | Keratoconjunctivitis Sicca | Corneal Endothelial Cell Loss | Iritis | Hyperpigmentation | Pruritus
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Denmark, Egypt, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, New Zealand, Peru, Philippines, Poland, Russia, Singapore, South Africa, Spain, Sweden, Thailand, Turkey, United Kingdom, United States
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Glaucoma|Glaucoma, Open-Angle|Hypertension
Phase 2: Cataract
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 192024-092 | P3 |
Unknown Status |
Unknown |
2026-12-31 |
|
| Maia | P3 |
Enrolling by invitation |
Glaucoma, Open-Angle|Hypertension |
2026-08-07 |
47% |
| 1698-301-007 | P3 |
Unknown Status |
Hypertension|Glaucoma, Open-Angle |
2025-08-28 |
|
| NCT03850782 | P3 |
Active, not recruiting |
Hypertension|Glaucoma, Open-Angle |
2025-08-09 |
47% |